Provided by Tiger Trade Technology Pte. Ltd.

Curis

0.9688
-0.0612-5.94%
Volume:247.90K
Turnover:247.38K
Market Cap:12.53M
PE:-0.30
High:1.05
Open:1.02
Low:0.9528
Close:1.03
52wk High:3.41
52wk Low:0.7710
Shares:12.93M
Float Shares:10.18M
Volume Ratio:0.85
T/O Rate:2.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2814
EPS(LYR):-6.8803
ROE:-2951.24%
ROA:-61.20%
PB:-0.85
PE(LYR):-0.14

Loading ...

Curis Inc. gibt Termin für Sonderaktionärstreffen bekannt

Reuters
·
11 hours ago

Curis Faces Nasdaq Delisting Risk After Compliance Monitoring Notice

Reuters
·
11 hours ago

Curis Targets BTKi-Exposed CLL With New Emavusertib Combo Trial: What Investors Should Watch

TIPRANKS
·
Jan 16

ADVISORY-Alert incorrectly tagged to Curis Inc withdrawn

Reuters
·
Jan 13

Curasight Announces Encouraging Preliminary Data From Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical Utreat in High-Grade Gliomas®

THOMSON REUTERS
·
Jan 13

Curis Announces PIPE Financing and Strategic Capital Strengthening

TIPRANKS
·
Jan 08

Crude Oil Down 2%; ISM Services PMI Surges In December

Benzinga
·
Jan 08

BRIEF-Curis Announces Pricing Of Private Placement Totaling Up To $80.8 Million In Gross Proceeds

Reuters
·
Jan 07

Press Release: Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Dow Jones
·
Jan 07

ADVISORY-Alert incorrectly tagged to Curis Inc withdrawn

Reuters
·
Dec 19, 2025

Curasight Announces Successful Dosing of First Patient in Phase 1 Trial With Utreat® in Brain Cancer

THOMSON REUTERS
·
Dec 19, 2025

Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study

Reuters
·
Dec 09, 2025

Curis Provides Updated Data From Its Frontline Aml Triplet Study

THOMSON REUTERS
·
Dec 09, 2025

Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting

Reuters
·
Nov 14, 2025

Analysts Offer Insights on Healthcare Companies: Curis (CRIS) and Intensity Therapeutics, Inc. (INTS)

TIPRANKS
·
Nov 13, 2025

Curis’s Strategic Clinical Advancements and Promising Data Drive Buy Rating

TIPRANKS
·
Nov 12, 2025

Curis Inc. Earnings Call: Clinical Progress and Financial Gains

TIPRANKS
·
Nov 09, 2025

Curis Completes Sale of Erivedge Business

TIPRANKS
·
Nov 07, 2025

Biotech firm Curis beats Q3 revenue estimates

Reuters
·
Nov 07, 2025

Curis Q3 EPS $(0.49) Beats $(0.58) Estimate, Sales $3.176M Beat $2.860M Estimate

Benzinga
·
Nov 07, 2025